Page 2 - Thierry Andre News Today

Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer

Surfs Up: Casablanca Drops Bespoke Surfboards and Swimwear: One-of-a-kind boards emblazoned with thematic patterns.

This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cook...

(2) KEYTRUDA Is First Checkpoint Inhibitor Approved in Europe to Treat MSI-H or dMMR Colorectal Cancer European Approval Based on Results From KEYNOTE-177 Trial Demonstrating KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 40% Compared With Chemotherapy Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission has approved KEYTRUDA, Mercks anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult pa...

This article is a collaboration between MedPage Today and: Almost 40% of progressive, advanced gastrointestinal (GI) tumors with mismatch repair deficiency (dMMR) responded to the investigational anti-PD-1 agent dostarlimab, according to a preliminary clinical trial. Overall, 38.7% of 106 patients responded to single-agent treatment with monoclonal antibody, including 36.2% of colorectal cancers (CRC) and 43.2% of all other tumors, which were primarily GI in origin. About three-fourths of pati...